Open AccessPharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and Pseudomonas aeruginosa bacteremia and/or pneumonia treated with extended infusion cefepime versus extended infusion piperacillin/tazobactam
Author(s) -
Anthony T. Gerlach,
Eric Wenzler,
Lauren N. Hunt,
José A. Bazan,
Karri A. Bauer
Publication year - 2019
Publication title -
international journal of critical illness and injury science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.274
H-Index - 12
eISSN - 2231-5004
pISSN - 2229-5151
DOI - 10.4103/ijciis.ijciis_70_18
Subject(s) - cefepime , medicine , tazobactam , piperacillin , piperacillin/tazobactam , bacteremia , pneumonia , pharmacodynamics , minimum inhibitory concentration , ventilator associated pneumonia , pharmacokinetics , streptococcus pneumoniae , intensive care unit , pseudomonas aeruginosa , loading dose , population , antibiotics , ceftazidime , microbiology and biotechnology , genetics , bacteria , biology , environmental health
We sought to correlate pharmacokinetic (PK)/pharmacodynamic (PD) predictions of antibacterial efficacy and clinical outcomes in patients with augmented renal clearance (ARC) and Pseudomonas aeruginosa bacteremia or pneumonia treated with extended infusion cefepime or piperacillin/tazobactam.